Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d] pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells

FASEB Journal

Volumn 22, Issue 5, 2008, Pages 1560-1571

  Spreafico, Adriano ^a   Schenone, Silvia ^b   Serchi, Tommaso ^a   Orlandini, Maurizio ^a   Angelucci, Adriano ^c   Magrini, David ^a   Bernardini, Giulia ^a   Collodel, Giulia ^a   Di Stefano, Anna ^a   Tintori, Cristina ^a   Bologna, Mauro ^b   Manetti, Fabrizio ^a   Botta, Maurizio ^a   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Apoptosis; Bone cancer; Bone cells; Osteoblast; Tyrosine kinase

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; DNA NUCLEOTIDYLEXOTRANSFERASE; HOE 33342; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; SRC KINASE INHIBITOR; SRC KINASE INHIBITOR 10; SRC KINASE INHIBITOR 26; SRC KINASE INHIBITOR 34; SRC KINASE INHIBITOR 35; SRC KINASE INHIBITOR 47; SRC KINASE INHIBITOR 54; SRC KINASE INHIBITOR 57; SRC KINASE INHIBITOR 58; SRC KINASE INHIBITOR 60; SRC KINASE INHIBITOR 61; SRC KINASE INHIBITOR 63; SRC KINASE INHIBITOR 65; SRC KINASE INHIBITOR 68; SRC KINASE INHIBITOR 70; SRC KINASE INHIBITOR 71; SRC KINASE INHIBITOR 72; SRC KINASE INHIBITOR 83; SRC KINASE INHIBITOR 85; SRC KINASE INHIBITOR 87; SRC KINASE INHIBITOR 88; SRC KINASE INHIBITOR S13; SRC KINASE INHIBITOR S7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MINERALIZATION; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; ENZYME REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VIVO STUDY; KINETICS; MALE; MOUSE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE DIFFERENTIATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; OSTEOSARCOMA; PYRAZOLES; PYRIMIDINES; SRC-FAMILY KINASES;

EID: 43249100853     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-9873com     Document Type: Article

References (53)

1. Hayden, J. B., and Hoang, H. H. (2006) Osteosarcoma: basic science and clinical implications. Orthop. Clin. N. Am. 37, 1-7
2. Longhi, A., Errani, C., De Paolis, M., Mercuri, M., and Bacci, G. (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 32, 423-436
3. Bruland, O. S., and Pihl, A. (1997) On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer 33, 1725-1731
4. Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., and Campanacci, M. (2000) Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J. Clin. Oncol. 18, 4016-4027
5. Marina, N., Gebhardt, M., Teot, L., and Gorlick, R. (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9, 422-441
6. Gorlick, R., Anderson, P., Andrulis, I., Arndt, C., Beardsley, G. P., Bernstein, M., Bridge, J., Cheung, N. K., Dome, J. S., Ebb, D., Gardner, T., Gebhardt, M., Grier, H., Hansen, M., Healey, J., Helman, L., Hock, J., Houghton, J., Houghton, P., Huvos, A., Khanna, C., Kieran, M., Kleinerman, E., Ladanyi, M., Lau, C., Malkin, D., Marina, N., Meltzer, P., Meyers, P., Schofield, D., Schwartz, C., Smith, M. A., Toretsky, J., Tsokos, M., Wexler, L., Wigginton, J., Withrow, S., Schoenfeldt, M., and Anderson, B. (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin. Cancer Res. 9, 5442-5453
7. Grimer, R. J. (2005) Surgical options for children with osteosarcoma. Lancet Oncol. 6, 85-92
8. Casas-Ganem, J., and Healey, J. H. (2005) Advances that are changing the diagnosis and treatment of malignant bone tumors. Curr. Opin. Rheumatol. 17, 79-85
9. Yeatman, T. J. (2004) A renaissance for SRC. Nat. Rev. Cancer 4, 470-480
10. Schenone, S., Bruno, O., Bondavalli, F., Ranise, A., Mosti, L., Menozzi, G., Fossa, P., Donnini, S., Santoro, A., Ziche, M., Manetti, F., and Botta, M. (2004). Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4- d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur. J. Med. Chem. 39, 939-946
11. Schenone, S., Bruno, O., Ranise, A., Bondavalli, F., Brullo, C., Fossa, P., Mosti, L., Menozzi, G., Carraro, F., Naldini, A., Bernini, C., Manetti, F., and Botta, M. (2004) New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg. Med. Chem. Lett. 14, 2511-2517
12. Carraro, F., Naldini, A., Pucci, A., Locatelli, G. A., Maga, G., Schenone, S., Bruno, O., Ranise, A., Bondavalli, F., Brullo, C., Fossa, P., Menozzi, G., Mosti, L., Modugno, M., Tintori, C., Manetti, F., and Botta, M. (2006). Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J. Med. Chem. 49, 1549-1561
13. Carraro, F., Pucci, A., Naldini, A., Schenone, S., Bruno, O., Ranise, A., Bondavalli, F., Brullo, C., Fossa, P., Menozzi, G., Mosti, L., Manetti, F., and Botta, M. (2004) Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J. Med. Chem. 47, 1595-1598
14. Angelucci, A., Schenone, S., Gravina, G. L., Muzi, P., Festuccia, C., Vicentini, C., Botta, M., and Bologna, M. (2006) Pyrazolo[3,4-d] pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur. J. Cancer 42, 2838-2845
15. Donnini, S., Monti, M., Castagnini, C., Solito, R., Botta, M., Schenone, S., Giochetti, A., and Ziche, M. (2007) Pyrazolopyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int. J. Cancer 120, 995-1004
16. Manetti, F., Pucci, A., Magnani, M., Locatelli, G. A., Brullo, C., Naldini, A., Schenone, S., Maga, G., Carraro, F., and Botta, M. (2007) Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells. Chem. Med. Chem. 2, 343-353
17. Schlessinger, J. (2000) New roles for Src kinases in control of cell survival and angiogenesis. Cell 100, 196-293
18. Recchia, I., Rucci, N., Funari, A., Migliaccio, S., Taranta, A., Longo, M., Kneissel, M., Susa, M., Fabbro, D., and Teti, A. (2004) Reduction of c-Src activity by substituted 5,7-diphenylpyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 34, 65-79
19. Missbach, M., Jeschke, M., Feyen, J., Muller, K., Glatt, M., Green, J., and Susa, M. (1999). A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24, 437-449
20. Šuša, M., and Teti, A. (2000) Tyrosine kinase src inhibitors: potential therapeutic applications. Drug News Perspect. 13, 169-175
21. Longo, M., Brama, M., Marino, M., Bernardini, S., Korach, K. S., Wetsel, W. C., Scandurra, R., Faraggiana, T., Spera, G., Baron, R., Teti A., and Migliaccio, S. (2004) Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation. Bone 34, 100-111
22. Azuma, K., Tanaka, M., Uekita, T., Inoue, S., Yokota, J., Ouchi, Y., and Sakai, R. (2005). Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 24, 4754-4764
23. Manara, M. C., Bernard, G., Lollini, P., Nanni, P., Zuntini, M., Landuzzi, L., Benini, S., Lattanzi, G., Sciandra, M., Serra, M., Colombo, M. P., Bernard, A., Picci, P., and Scotlandi, K. (2006) CD99 acts as an oncosuppressor in osteosarcoma. Mol. Biol. Cell 17, 1910-1921
24. Spreafico, A., Frediani, B., Capperucci, C., Chellini, F., Paffetti, A., D'Ambrosio, C., Bernardini, G., Mini, R., Collodel, G., Scaloni, A., Marcolongo, R., and Santucci, A. (2006) A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics 6, 3520-3532
25. Frediani, B., Spreafico, A., Capperucci, C., Chellini, F., Gambera, D., Ferrata, P., Baldi, F., Falsetti, P., Santucci, A., Bocchi, L., and Marcolongo, R. (2004) Long-term effects of neridronate on human osteoblastic cell cultures. Bone 35, 859-869
26. Bondavalli, F., Botta, M., Bruno, O., Ciacci, A., Corelli, F., Fossa, P., Lucacchini, A., Manetti, F., Martini, C., Menozzi, G., Mosti, L., Ranise, A., Schenone, S., Tafi, A., and Trincavellic, M. L. (2002) Synthesis, molecular modeling studies, and pharmacological activity of selective A1 receptor antagonists. J. Med. Chem. 45, 4875-4887
27. Moasser, M. M., Srethapakdi, M., Sachar, K. S., Kraker, A. J., and Rose, N. (1999) Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59, 6145-6152
28. Golubovskaya, V. M., Gross, S., Kaur, A. S., Wilson, R. I., Xu, L. H., Yang, X. H., and Cance, W. G. (2003) Simultaneous inhibition of focal adhesion kinase and Src enhances detachment and apoptosis in colon cancer cell lines. Mol. Cancer Res. 1, 755-764
29. Liu, Z., Falola, J., Zhu, X., Gu, Y., Kim, L. T., Sarosi, G. A., Anthony, T., and Nwariaku, F. E. (2004) Antiproliferative effects of Src inhibition on medullary thyroid cancer. J. Clin. Endocrinol. Metab. 89, 3503-3509
30. Boyd, D. D., Wang, H., Avila, H., Parikh, N. U., Kessler, H., Magdolen, V., and Gallick, G. E. (2004) Combination of an Src Kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin. Cancer Res. 10, 1545-1555
31. Angers-Loustau, A., Hering, R., Werbowetski, T. E., Kaplan, D. R., and Del Maestro, R. F. (2004) SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. 2, 595-605
32. Contri, A., Brunati, A. M., Trentin, L., Cabrelle, A., Miorin, M., Cesaro, L., Pinna, L. A., Zambello, R., Semenzato, G., and Donella-Deana, A. (2005) Chronic lymphocytic leukaemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 115, 369-378
33. Lee, M., Kim, J. Y., and Koh, W. S. (2004) Apoptotic effect of PP2 a Src tyrosine kinase Inhibitor, in murine B cell leukemia. J. Cell. Biochem. 93, 629-638
34. Nam, J. S., Ino, Y., Sakamoto, M., and Hirohashi, S. (2002) Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8, 2430-2436
35. Schenone, S., Bruno, O., Bondavalli, F., Ranise, A., Mosti, L., Menozzi, G., Fossa, P., Manetti, F., Morbidelli, L., Trincavelli, L., Martini, C., and Lucacchini, A. (2004) Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H- pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation. Eur. J. Med. Chem. 39, 153-160
36. Ren, S., Gao, C., Zhang, L., Koike, K., and Tsuchida, N. (2003) PI3K inhibitors changed the p53-induced response of Saos-2 cells from growth arrest to apoptosis. Biochem. Biophys. Res. Commun. 308, 120-125
37. Diaz-Montero, C. M., Wygant, J. N., and McIntyre, B. W. (2006) PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur. J. Cancer 42, 1491-1500
38. Brunton, V. G., Avizienyte, E., Fincham, V. J., Sorrels, B., Metcalf, C. A., Sawyer, T. K., and Frame, M. C. (2005) Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behaviour. Cancer Res. 65, 1335-1342
39. Daigo, Y., Furukawa, Y., Kawasoe, T., Ishiguro, H., Fujita, M., Sugai, S., Nakamori, S., Liefers, G. J., Tollenaar, R. A., van de Velde, C. J., Nakamura, Y. (1999) Absence of genetic alteration at codon 531 of the human c-Src gene in 479 advanced colerectal cancer from Japanese and Caucasian patients. Cancer Res. 59, 4222-4224
40. Nilbert, M., and Fernebro, E. (2000) Lack of activating of c-SRC mutation at codon 531 in rectal cancer. Cancer Genet. Cytogenet. 121, 94-95
41. Shor, A. C., Keschmann, E. A., Lee, F. Y., Muro-Cacho, C., Letson, G. D., Trent, J. C., Pledger, W. J., and Jove, R. (2007) Desatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res. 67, 2800-2808
42. Lowe, C., Yoneda, T., Boyce, B. F., Chen, H., Mundy, G. R., and Soriano, P. (1993) Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. U. S. A. 90, 4485-4489
43. Amling, M., Neff, L., Priemel, M., Priemel, A. F., Schilling, A. F., Rueger, J. M., and Baron, R. (2000) Progressive increase in bone mass and development of odontomas in aging osteopetrotic c-Src deficient mice. Bone 27, 603-610
44. Perez, M., Migliaccio, S., Taranta, A., Festuccia, C., Orrù , L., Brama, M., Bologna, M., Farraggiana, T., Baron, R., and Teti, A. (2001) Melanoma cells stimulate osteoclastogenesis, c-src expression and osteoblast cytokines. Eur. J. Cancer 37, 629-640
45. Marzia, M., Sims, N. A., Voit, S., Migliaccio, S., Taranta, A., Bernardini, S., Faraggiana, T., Yoneda, T., Mundy, G. R., Boyce, B. F., Baron, R., and Teti, A. (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151, 311-320
46. Zaidi, S. K., Sullivan, A. J., Medina, R., Ito, Y., van Wijnen, A. J., Stein, J. L., Lian, J. B., and Stein, G. S. (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23, 790-799
47. McAllister, R. M., Gardner, M. B., Greene, A. E., Bradt, C., Nichols, W. W., and Landing, B. H. (1971) Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27, 397-402
48. Luu, H. H., Kang, Q., Park, J. K., Si, W., Luo, Q., Jiang, W., Yin, H., Montag, A. G., Simon, M. A., Peabody, T. D., Haydon, R. C., Rinker-Schaeffer, C. W., and He, T. C. (2005) A orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metast. 22, 319-329
49. Fuchs, B., Mahlum, E., Halder, C., Maran, A., Yaszeminski, M., Bode, B., Bolander, M., and Sarkar, G. (2007). High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene 399, 137-143
50. Dass, C. R., Ek, E. T., Contreras, K. G., and Choong, P. F. (2006) A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin. Exp. Metast. 23, 367-380
51. Orimo, H., and Shimada, T. (2006) Effects of phosphates on the expression of tissue-nonspecific alcaline phosphatase gene and phosphate-regulating genes in short-term cultures of human osteosarcoma cell lines. Mol. Cell. Biol. 282, 101-108
52. Longo, M., Peruzzi, B., Fortunati, D., De Luca, V., Denger, S., Caselli, G., Migliaccio, S., and Teti, A. (2006) Modulation of human estrogen receptor alpha F promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells. J. Mol. Endocrinol. 37, 489-502
53. Kaolan, K. B., Swedlow, J. R., Morgan, D. O., and Varmus, H. E. (1995) c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 9, 1505-1517